急性虚血性脳卒中治療薬の市場規模、シェア、成長分析、診断別、薬剤クラス別、地域別 - 産業予測、2025～2032年

急性虚血性脳卒中治療薬の世界市場規模は、2023年に84億米ドルと評価され、予測期間（2025-2032年）にCAGR 8.7%で成長し、2024年の91億3,000万米ドルから2032年には178億米ドルに成長する見通しです。

急性虚血性脳卒中治療薬の世界市場は、脳血管疾患の有病率の増加や、先進的な血栓溶解薬や機械的血栓除去術の採用の高まりによって、大きな成長を遂げています。この市場に拍車をかけている主な要因は、高血圧、糖尿病、心房細動などの生活習慣に関連した危険因子の発生率が上昇していることであり、これらの危険因子は脳卒中リスクを上昇させ、タイムリーな介入の必要性を高めています。しかし、特に医療が行き届いていない地域では、高い治療費と不十分な診断インフラがアクセシビリティを阻害していることに加え、治療対象が限定される治療ウィンドウの狭さが課題となっています。北米は、強い認知度、強固なヘルスケアシステム、有利な償還慣行に支えられ、市場を独占しています。一方、脳卒中治療とAI診断への継続的な投資は、この分野の成長をさらに促進することが期待されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 顧客購買行動分析

急性虚血性脳卒中治療薬市場規模：診断別& CAGR（2025-2032）

• 市場概要
• CT
• MRI
• 頸動脈超音波検査
• 脳血管造影検査

急性虚血性脳卒中治療薬市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 組織プラスミノーゲン活性化因子
• 抗凝固剤
• 抗血小板薬
• 降圧剤

急性虚血性脳卒中治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Amgen Inc.（United States）
• Pfizer Inc.（United States）
• Sanofi S.A.（France）
• Novartis International AG（Switzerland）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• GlaxoSmithKline plc（United Kingdom）
• AbbVie Inc.（United States）
• Bayer AG（Germany）
• Bristol Myers Squibb（United States）
• AstraZeneca plc（United Kingdom）
• Eli Lilly and Company（United States）
• Takeda Pharmaceutical Company Limited（Japan）

結論と提言

Global Acute Ischemic Stroke Therapeutics Market size was valued at USD 8.4 billion in 2023 and is poised to grow from USD 9.13 billion in 2024 to USD 17.8 billion by 2032, growing at a CAGR of 8.7% during the forecast period (2025-2032).

The global market for acute ischemic stroke therapeutics is witnessing significant growth, driven by the increasing prevalence of cerebrovascular diseases and the heightened adoption of advanced thrombolytics and mechanical thrombectomy techniques. A major factor fueling this market is the rising incidence of lifestyle-related risk factors such as hypertension, diabetes, and atrial fibrillation, which elevate stroke risk and heighten the necessity for timely interventions. However, challenges persist due to the narrow therapeutic window that limits treatment eligibility, especially in underserved areas, alongside high treatment costs and inadequate diagnostic infrastructure that hinder accessibility. North America dominates the market, supported by strong awareness, robust healthcare systems, and favorable reimbursement practices, while ongoing investments in stroke care and AI diagnostics promise to further propel growth in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Ischemic Stroke Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Ischemic Stroke Therapeutics Market Segments Analysis

Global Acute Ischemic Stroke Therapeutics Market is segmented by Diagnosis, Drug Class and region. Based on Diagnosis, the market is segmented into CT, MRI, Carotid Ultrasound and Cerebral Angiography. Based on Drug Class, the market is segmented into Tissue Plasminogen Activator, Anticoagulant, Antiplatelet and Antihypertensive. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Ischemic Stroke Therapeutics Market

The global acute ischemic stroke therapeutics market is significantly influenced by the rising prevalence of stroke, especially within aging demographics. As strokes represent a leading cause of disability and mortality worldwide, the demand for effective treatments has surged. The increasing life expectancy across various populations has heightened the vulnerability to strokes, resulting in a greater need for advanced therapeutics such as thrombolytics, neuroprotective agents, and mechanical thrombectomy techniques. This growing awareness and need for timely and effective intervention in stroke management continue to propel the development and availability of innovative therapeutic solutions in the market.

Restraints in the Global Acute Ischemic Stroke Therapeutics Market

A significant challenge in addressing ischemic stroke lies in the limited treatment window, usually within a few hours for effective thrombolysis. Delays in recognizing symptoms and reaching medical facilities often result in missed chances for treatment. This issue is further compounded in many low- and middle-income areas, where limited access to advanced imaging technologies and a shortage of trained stroke specialists can lead to delays in diagnosis and intervention. Such barriers ultimately restrict the availability and implementation of therapeutic options, hindering the overall management of acute ischemic stroke in affected populations.

Market Trends of the Global Acute Ischemic Stroke Therapeutics Market

The Global Acute Ischemic Stroke Therapeutics market is witnessing a transformative trend driven by the integration of personalized medicine and Artificial Intelligence (AI). By leveraging AI to accurately assess clot locations, predict treatment responses, and inform therapeutic decisions, healthcare providers are enhancing the efficacy of acute stroke interventions. Coupled with advancements in genomics and biomarkers, this trend is fostering more targeted treatment approaches, resulting in optimized patient outcomes. Hospitals that implement AI-assisted stroke triage systems are demonstrating significant improvements in crucial metrics, such as reduced door-to-needle times, which is further propelling interest and investment in innovative stroke care solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Acute Ischemic Stroke Therapeutics Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• CT
• MRI
• Carotid Ultrasound
• Cerebral Angiography

Global Acute Ischemic Stroke Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Tissue Plasminogen Activator
• Anticoagulant
• Antiplatelet
• Antihypertensive

Global Acute Ischemic Stroke Therapeutics Market Size & CAGR (2025-2032)

• North America (Diagnosis, Drug Class)
  • US
  • Canada
• Europe (Diagnosis, Drug Class)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Drug Class)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Drug Class)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Drug Class)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations